Founded in 2014 and based in New York City, ExSight Ventures focuses on early-stage investments in companies developing ophthalmic diagnostic and treatment solutions. They have a preference for founders of portfolio startups and invest primarily in the United States. The fund specializes in the areas of genetics and biotechnology. Notable investments include ONL Therapeutics, RetroSense Therapeutics, and LensGen Inc. The firm typically invests in startups that are 6-10 years old and has been most active in 2017. ExSight Ventures has a lower number of lead investments compared to other companies and is involved in less than 2 deals per year. They typically invest in rounds with 5 participants and in deals ranging from $10 to $50 million. In addition to ExSight Ventures, startups in this field are often financed by National Institutes of Health, MedTech Innovator, and Tech Coast Angels.